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The Borna disease virus (BDV) replicates in the nucleus. The viral p40 protein (N), which is found abundantly in the nucleus
in BDV-infected cells, may play an important role in virus replication. To analyze the amino acid residues involved in the
nuclear targeting of BDV N, a series of eukaryotic expression plasmids encoding deletion mutants of N was constructed and
transfected into COS-7 cells. In indirect immunofluorescence assays with a rabbit anti-BDV N antiserum, wild-type N was
located in the nucleus of transfected cells in the absence of other viral constituents. In contrast, mutants lacking the 13
NH2-terminal amino acid residues 1MPPKRRLVDDADA13 in common gave a cytoplasmic localization pattern. Similarly, a
mutant with substitution of 4KRR6 by 4NSG6 was retained in the cytoplasm. Furthermore, a nonapeptide, 3PKRRLVDDA11,
derived from the NH2-terminal region of N conferred nuclear targeting activity to b-galactosidase, which normally resides in
the cytoplasm. Thus, we have identified the nuclear targeting signal of the BDV N and narrowed it to the NH2-terminal region
where 4KRR6 basic amino acid residues are located. © 1998 Academic Press
INTRODUCTION
Borna disease virus (BDV) is the causative agent of a
progressive encephalopathy of animals (Ludwig et al.,
1988; Stitz et al., 1993). Molecular characterization of
horse-derived BDV showed that BDV is an enveloped,
nonsegmented, negative-stranded (NNS) RNA virus
(Briese et al., 1992, 1994; Cubitt and de la Torre, 1994)
and a prototype of Bornaviridae. Its viral genome con-
sists of at least five major open reading frames (ORFs).
ORF I encodes 38- and 40-kilodalton (kDa) proteins; ORF
II encodes a 24-kDa phosphoprotein; ORF III encodes an
18-kDa glycoprotein; ORF IV encodes proteins of 56/64
kDa which are glycosylated to give rise to glycoproteins
of 84/94 kDa, respectively; and ORF V has the capacity to
encode a protein of 170–190 kDa (Briese et al., 1994;
Scha¨dler et al., 1985; Cubitt et al., 1994; de la Torre, 1994;
Gonzalez-Dunia et al., 1997; Kliche et al., 1994; Lipkin et
al., 1990; MacClure et al., 1992; Pyper et al., 1993;
Schneemann et al., 1995; Schneider et al., 1997; Thiede-
mann et al., 1992; Thierer et al., 1992). The functions of
these proteins are not known. However, based on the
genomic locations of the ORFs, and what we know about
other animal NNS-RNA viruses, the p40 encoded by ORF
I is likely a nucleocapsid protein (N) analogous to the NP
in rhabdo- and paramyxoviridae of the Mononegavirales,
whereas the p24 encoded by ORF II and a protein of
170–190 kDa encoded by ORF V may be the BDV equiv-
alents of the phosphoprotein P/NS and the polymerase
protein L, respectively (Kingsbury, 1990; Wagner, 1990).
These three proteins, i.e., the N, P/NS, and L proteins,
are tightly associated with the full-length viral genomic
RNA to form the ribonucleoprotein core which is the
minimal essential infectious unit for NNS-RNA viruses
(Kingsbury, 1990; Wagner, 1990). The demonstration of
infectious ribonucleoprotein complexes in BDV-infected
cells (Cubitt and de la Torre, 1994) suggests that BDV
may employ a comparable strategy in its replication and
assembly. However, unlike other known animal NNS-
RNA viruses (Kingsbury, 1990; Wagner, 1990), BDV repli-
cates in the nucleus (Briese et al., 1992; Cubitt and de la
Torre, 1994). For viral replication to occur in the nucleus,
the viral proteins of the ribonucleoprotein complexes,
synthesized in the cytoplasm of the BDV-infected cells,
must be imported into the nucleus. Consistent with this
hypothesis, the antibody against the BDV N detected the
antigen mainly in the nucleus of BDV-infected cells, al-
though smaller amounts are detectable in the cytoplasm
as well (Bause-Niedrig et al., 1991; Haas et al., 1986;
Thiedemann et al., 1992). Western blot analysis consis-
tently showed a doublet of p38/40 protein reactive with
anti-N antibody in BDV-infected cells (Hsu et al., 1994).
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Recently, Pyper and Gartner (1997) reported that the p38
N species is lacking NH2-terminal 13 amino acid resi-
dues of p40 N and showed that p40 N targeted to the
nucleus but p38 N was distributed in both nucleus and
cytoplasm. Based on these findings, they assumed that
the nuclear targeting activity was associated with NH2-
terminal 13 amino acid residues of N.
Nuclear targeting of many nucleoproteins has been
documented to be mediated by nuclear localization sig-
nals (NLS), which can be classified into two major
classes, such as short sequences rich in positively
charged amino acids and nonpositive NLS (Boulikas,
1993). Among them, the positively charged NLSs have
been studied in more detail than the other. In the
BDV N protein, three basic amino acid motifs, 4KRR6,
163KKRFK167, and 338RYRRREISR346, have been regarded
as candidates for NLS. Here, we provide evidence that
the nuclear targeting activity of BDV N is associated with
the 9 amino acid residues in the NH2-terminal region and
the 4KRR6 sequence within it is required for nuclear
targeting activity.
RESULTS
Nuclear localization of BDV N in cells infected with
BDV and transfected with a BDV N expression
plasmid
The specificity of the rabbit antiserum to BDV N was
verified by Western blotting with cell lysates prepared
from MDCK and MDCK/BDV cells (Fig. 2A). The anti-
serum gave a strong band of 40 kDa and a weak band of
38 kDa when reacted with the MDCK/BDV cell lysate, but
FIG. 1. (A) Construction of BDV N expression plasmids. pTrc-N.Wild was constructed by inserting a BDV N cDNA immediately downstream of, and
in-frame with, the six histidines in the pTrc-His B plasmid (Invitrogen). pGEX-N.Wild encoding the GST-BDV N fusion protein was constructed by
subcloning of the BDV N cDNA into the pGEX-5X-3 vector (Pharmacia). pcDL-N.Wild was constructed by inserting the BDV N cDNA downstream of,
and in-frame with, the DNA fragment encoding HA of the pcDL-HA plasmid modified from pcDL-SRa296 (Takebe et al., 1988) by addition of the Kozak
sequence and the HA sequence. (B) Schematic presentation of the deletion and substitution mutants of BDV N inserted into pcDL-HA. Bars indicate
the regions deleted. BAS represents basic amino acid stretch. (C) Primers and an adaptor used for plasmid construction. Bold letters indicate BDV
N-specific nucleotides. Underlined letters represent nucleotides substituted. Nucleotide numbering follows that previously reported for a horse-
derived BDV, strain V (the EMBL Databank, Accession No. U046080).
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did not react with the MDCK cell lysate. This antiserum
also stained the MDCK/BDV cells in IFA, showing gran-
ular and focal fluorescence in the nucleus and faint
staining in the cytoplasm (Fig. 2Bb), typically seen for
BDV-infected cells stained with virus-specific antibodies
(Herzog and Rott,1980; Rott et al., 1985). Noninfected
MDCK cells were not stained with this antiserum (Fig.
2Ba). Neither the antiserum preabsorbed with a GST-
BDV N fusion protein expressed in E.coli nor the preim-
mune rabbit serum stained the MDCK/BDV cells (data
not shown). Thus, the antiserum used here specifically
detected BDV N, which was localized predominantly in
the nucleus, consistent with the previous reports for the
subcellular localization of BDV N (Bause-Niedrig et al.,
1991; Haas et al., 1986; Ludwig et al., 1988; Thiedemann
et al., 1992).
To determine whether BDV N can localize to the nu-
cleus in the absence of other BDV proteins, COS-7 cells
were transfected with pcDL-N.Wild and analyzed with
antiserum by Western blot (Fig. 2A) and IFA (Fig. 2B).
Western blot detected a single band of approximately 40
kDa in the lysate of transfected cells, but not in cell
lysates of either untransfected COS-7 cells or cells trans-
fected with pcDL-HA. In IFA, the N protein was located in
the nucleus of COS-7 cells by IFA, 48 h after transfection
with pcDL-N.Wild (Figs. 2Be and 2Bm). The nuclear ma-
trix but not the nucleolus was stained. The fluorescence
was intensive and homogeneous, distinct from the focal
staining within the nucleus characteristically seen in
MDCK/BDV cells (Fig. 2Bb). The antiserum did not react
with COS-7 cells that were not transfected (Fig. 2Bd) or
transfected with pcDL-HA (Fig. 2Bc). IFA staining of
pcDL-N.Wild-transfected COS-7 cells with a mouse
monoclonal antibody to the HA epitope gave essentially
the same results (data not shown).
Subcellular localization of proteins expressed by
deletion mutants of BDV N
Short sequences rich in basic amino acid frequently
serve as the nuclear localization signals for proteins in
eukaryotes (reviewed by Boulikas, 1993). BDV N contains
three such sequences, 4KRR6 (BAS1), 163KKRFK167
(BAS2), and 338RYRRREISR346 (BAS3), located at the NH2-
terminal, the middle, and the COOH-terminal regions of
the molecule, respectively. In order to define the se-
quence having nuclear targeting activity in BDV N, eu-
karyotic expression plasmids encoding a series of BDV
N mutants with deletions were constructed (Fig. 1B). The
plasmids pcDL-del.N92, pcDL-del.N147, and pcDL-
del.N369 encoded N mutants lacking the 13, 32, and 105
amino acid residues from the NH2-terminus, respectively.
Among them, pcDL-del.N92 encoded a predicted protein
equivalent to p38 N (Pyper and Gartner, 1997). pcDL-
del.M375 and pcDL-del.BAS2 encoded N mutants which
lacked the 130 amino acid residues in the middle and
BAS2, respectively. pcDL-del.C1085, pcDL-del.C940, and
pcDL-del.C738 encoded N mutants lacking 27, 77, and
143 amino acid residues from the COOH-terminus, re-
spectively. The pcDL-del.BAS3 plasmid encoded an N
mutant lacking BAS3.
After transfection of COS-7 cells with each of the
plasmid constructs, the proteins expressed in trans-
fected cells were analyzed by Western blots with anti-
BDV N antiserum (Fig. 2A). Proteins of expected sizes
FIG. 2. The expression and subcellular localization of the wild-type N protein and its deletion mutants. (A) Expression of the N wild-type and deletion
mutants detected by Western blot with a rabbit anti-BDV N antiserum at 1:300 dilution. (B) IFA staining of transfected COS-7 cells with rabbit anti-BDV
N antiserum at 1:500 dilution. Cells were examined with a confocal laser scanning microscope. Magnification was 1003. COS-7 cells were
transfected with pcDL-HA (c), pcDL-N.Wild (e and m), pcDL-del.N92 (f), pcDL-del.N147 (g), pcDL-del.N369 (h), pcDL-del.C1085 (i), pcDL-del.C940 (j),
pcDL-del.C738 (k), pcDL-del.M375 (l), pcDL-del.BAS2 (n), and pcDL-del.BAS3 (o), respectively. Staining of MDCK cells persistently infected with BDV
(MDCK/BDV) is shown in b. MDCK cells not infected (MDCK/2) (Aa) and COS-7 cells not transfected (COS-7/2) (Ad) served as negative controls.
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were detected in COS-7 cells transfected with the series
of expression plasmids encoding the N mutants.
Subcellular localization of BDV N in COS-7 cells trans-
fected with plasmids encoding the wild-type and mutant
N was analyzed by IFA with the N-specific antiserum
(Fig. 2B). Deletion mutants of BDV N in cells transfected
with pcDL-del.N92 (Fig. 2Bf), pcDL-del.N147 (Fig. 2Bg),
and pcDL-del.N369 (Fig. 2Bh) were located in the cyto-
plasm. These three N mutants lacked the NH2-termi-
nal 13 amino acid residues in common. In contrast,
cells transfected with pcDL-del.C1085 (Fig. 2Bi), pcDL-
del.C940 (Fig. 2Bj), pcDL-del.C738 (Fig. 2Bk), pcDL-
del.M375 (Fig. 2Bl), pcDL-del.BAS2 (Fig. 2Bn), and pcDL-
del.BAS3 (Fig. 2Bo) gave nuclear staining, although only
the cells transfected with pcDL-del.BAS3 gave spot-like
staining (Fig. 2Bo). These N mutants conserved the NH2-
terminal 13 amino acid residues, 1MPPKRRLVDDADA13,
of BDV N. IFA with the anti-HA monoclonal antibody gave
results similar to those seen in IFA with the anti-BDV N
antiserum (data not shown). Thus, nuclear targeting ac-
tivity may be associated with the 13 NH2-terminal amino
acid residues including the BAS1 motif, but not the mid-
FIG. 2—Continued
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dle and COOH-terminal regions including the BAS2 and
BAS3 motifs, respectively, of BDV N.
Subcellular localization of BDV N with substitution at
basic amino acid stretches
To confirm the nuclear localization potential of the
short basic amino acid stretches of BDV N, eukaryotic
expression plasmids pcDL-sub.BAS1, pcDL-sub.BAS2,
and pcDL-sub.BAS3 were constructed. These plasmids
encoded for N mutants with substitutions of 4KRR6 by
4NSG6 in BAS1, 163KKR165 by 163NTS165 in BAS2, and
340RRR342 by 340TSG342 in BAS3, respectively. Transfec-
tion of pcDL-sub.BAS1, pcDL-sub.BAS2, and pcDL-sub-
.BAS3 into COS-7 cells gave expression of N mutants
recognized by the N-specific antiserum in Western blots
(Fig. 3A). In IFA with N-specific antiserum (Fig. 3B), the
fluorescence pattern given by the BAS1-substituted N
(Fig. 3Ba) was comparable to that of the 13 NH2-terminal
amino acid-deleted N (Fig. 2Bf) being localized solely to
the cytoplasm. In contrast, COS-7 cells transfected with
pcDL-sub.BAS2 (Fig. 3Bb) and pcDL-sub.BAS3 (Fig. 3Bc)
gave nuclear staining. The N mutant having the BAS3
substitution gave the same picture as the BAS3-deleted
N mutant (compare Fig. 2Bo and 3Bc). We also con-
structed the double mutant pcDL-sub.BAS2-3 with sub-
stitution at BAS2 and BAS3 and transfected it into COS-7
cells. This doubly substituted N mutant is also trans-
ported in the nucleus (Fig. 3Bd). These results were
reproducible in IFA with the anti-HA monoclonal antibody
(Fig. 3C). Thus, we confirmed that the NH2-terminal re-
gion of BDV N, especially the 4KRR6 motif, is essential for
the nuclear targeting of BDV N, but the 163KKRFK167
(BAS2) and 338RYRRREISR346 (BAS3) motifs are not.
Nuclear import of b-galactosidase fused with 9 amino
acid residues from the NH2-terminal region of BDV N
The abrogation of nuclear localization of BDV N after
deletion of the NH2-terminal 13 amino acids or substitu-
FIG. 3. The expression and subcellular localization of the N substitution mutants. (A) Western blot analyses of the expressed proteins by use of
an anti-BDV N antiserum and visualized by the ECL detection system (Amersham). (B) IFA staining of transfected COS-7 cells by use of the anti-BDV
N antiserum. (C) IFA staining of transfected COS-7 cells by use of a mouse monoclonal antibody (Boehringer Mannheim) to the 12CA5 epitope of HA.
COS-7 cells were transfected with pcDL-sub.BAS1 (a), pcDL-sub.BAS2 (b), pcDL-sub.BAS3 (c), and pcDL-sub.BAS2-3 (d). COS-7 cells transfected with
pcDL-HA served as an HA-expression control (e), whereas COS-7 cells not transfected served as a negative control (f).
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tion of the BAS1 motif (4KRR6) by 4NSG6 in the above
experiments suggests, but does not prove, that this se-
quence is sufficient for the nuclear targeting of BDV N. To
address this issue, a eukaryotic expression plasmid,
pRSV-N.LacZ, which encoded a protein consisting of the
nonapeptide 3PKRRLVDDA11 from the NH2-terminal re-
gion of BDV N fused to the b-galactosidase protein, was
constructed and transfected into COS-7 cells. The pRSV-
LacZ and pRSV-HA plasmids served as controls. In West-
ern blot (Fig. 4A), the 3PKRRLVDDA11-b-galactosidase
fusion protein (Fig. 4A, lane d) and the b-galactosidase
protein (Fig. 4A, lane a) were specifically recognized by
an anti-b-galactosidase monoclonal antibody. No protein
reactive with the anti-b-galactosidase monoclonal anti-
body was detected in COS-7 cells not transfected (Fig.
4A, lane c) or transfected with pRSV-HA (Fig. 4A, lane b).
In IFA (Fig. 4B), the fusion protein gave a nuclear staining
pattern in COS-7 cells transfected with pRSV-N.LacZ (Fig.
4Bd). In contrast, the b-galactosidase protein was de-
tected only in the cytoplasm in cells transfected with
pRSV-LacZ (Fig. 4Ba). No fluorescence was detected in
cells not transfected (Fig. 4Bc) or transfected with
pRSV-HA (Fig. 4Bb). These results establish that the 9
amino acid residues, 3PKRRLVDDA11, present in the NH2-
terminal region of BDV N are necessary and sufficient for
its nuclear localization.
DISCUSSION
The minimal replication unit of NNS-RNA viruses is the
viral RNA genome tightly associated with the N, P, and L
proteins. As BDV replicates in the nucleus of the infected
cells, viral proteins, such as p40 (N), p24 (P), and the L
polymerase, necessary for this process must be im-
ported to the nucleus from the cytoplasm, where they are
synthesized. However, the mechanism of nuclear target-
ing of these proteins are largely unknown. We have
analyzed the nuclear targeting activity of BDV N sys-
tematically, and present here evidence that the
3PKRRLVDDA11 sequence, wherein the 4KRR6 motif ex-
ists, is necessary and sufficient for nuclear targeting of
BDV N. First, while mutant proteins lacking the central
and COOH-terminal sequences were localized to the
nucleus, all mutant proteins lacking the NH2-terminal 13
amino acid residues in common are localized in the
cytoplasm. Pyper and Gartner (1997) tested Cytomega-
rovirus-promoter-driven p40 N and p38 N expression
plasmids and found that p40 N was located to the nu-
cleus, but p38 N was present in both the nucleus and the
cytoplasm. From these results they also assumed that
the nuclear localization signal of p40 N might be asso-
ciated with the NH2-terminal 13 amino acid residues.
Differing from the finding of Pyper and Gartner (1997),
transfection of COS-7 cells with the pcDL-del.N92 plas-
mid encoding p38 N, lacking the NH2-terminal 13 amino
acid residues, gave only cytoplasmic staining in this
study. There was no nuclear staining. The reason for the
discrepancy between our results and those of Pyper and
Gartner (1997) is not clear. However, all our deletion
mutants lacking these 13 amino acid residues at the
NH2-terminal region gave cytoplasmic localization. Sec-
ond, although three basic amino acid stretches, BAS1,
BAS2, and BAS3, present in BDV N are candidates for the
nuclear localization signal, only the mutation at BAS1
abrogated the nuclear localization of N, and the mutation
at either BAS2 and BAS3 (Figs. 3Bb and 3Bc) or both (Fig.
3Bd) did not affect the nuclear targeting of N. Third, the
9 amino acid residues from the NH2-terminal region of
BDV N conferred nuclear targeting activity to b-galacto-
sidase which is normally expressed in the cytoplasm.
In BDV-infected cells, the protein recognized by BDV
N-specific antisera was present mainly in the nucleus,
although the cytoplasm was also stained weakly (Bause-
FIG. 4. The expression and subcellular localization of b-galactosi-
dase fused to a nonapeptide of BDV N. The pRSV-N.LacZ plasmid
encoding b-galactosidase fused to the nine NH2-terminal amino acid
residues of BDV N was used to transfect COS-7 cells. (A) Expression of
fusion protein was examined by Western blot by use of a mouse
anti-b-galactosidase monoclonal antibody and visualized by the ECL
detection system (Amersham). (B) IFA staining of transfected COS-7
cells by use of the same antibody at 1:100 dilution. COS-7 cells were
transfected with pRSV-LacZ (a), pRSV-HA (b), and pRSV-N.LacZ (d),
respectively. COS-7 cells not transfected (COS-7/2) served as a neg-
ative control (c).
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Niedrig et al., 1991; Haas et al., 1986; Ludwig et al., 1988;
Thiedemann et al., 1992; Fig. 2Bb). When pcDL-N.Wild
encoding BDV N was transfected into COS-7 cells, in the
absence of other viral components, staining was almost
exclusively localized to the nucleus (Fig. 2Be). BDV N in
the nucleus was seen as spot-like, with a focal appear-
ance (Fig. 2Bb). A likely explanation for this staining
pattern is that it represents staining of N in the ribonu-
cleoprotein complex. In contrast, the N protein in the
nucleus of COS-7 transfectants appeared as an intensive
smear. This may represent staining of N by itself which
was overexpressed in COS-7 cells after transfection. The
nuclear staining patterns of the N mutants with deletions
or substitutions gave staining patterns similar to that of
wild-type N; however, pcDL-del.BAS3 (Fig. 2Bo) and
pcDL-sub.BAS3 (Fig. 3Bc) gave spot-like appearances in
the nucleus. The reason for this nuclear localization
pattern is unknown, but deletion or substitution of short
amino acid stretches at the COOH-terminal portion might
have caused conformational changes leading BDV N to
aggregate or associate with other cellular components.
A short peptide with four arginines and lysines has
been proposed as a good candidate for a type of core
NLS (Boulikas, 1993). In addition, a proline residue,
which is a helix-breaking amino acid, is frequently found
at the NH2-terminal side of NLSs in the SV40 large T
antigen (PKKKRKV), SV40 VP2 (PNKKKRK), the polyoma
virus large T antigen (PKKAREDVSRKRPR), and the influ-
enza A virus NS1 protein (PFLDRLRRDQK and PKQKRK-
MAR) (proposed by Dang and Lee, 1989; reviewed by
Boulikas, 1993). In accord with these NLSs, the amino
acid residues, which are required for the nuclear target-
ing of BDV N, possess a proline residue at the NH2-
terminal side followed by lysine–arginine–arginine. Thus,
the basic amino acid motif of BDV N is similar to the
NLSs identified in the many other viral nucleoproteins,
except for one of the NLSs identified in the influenza
virus nucleoprotein which is not a basic amino acid motif
(Wang et al., 1997).
In MDCK/BDV cells, the proteins stained with a BDV
N-specific antiserum are localized mostly in the nucleus,
but weak staining is commonly seen in the cytoplasm as
well. In COS-7 cells transfected with pcDL-N.Wild, the
staining of cytoplasm was extremely low. This finding
suggests that pcDL-N.Wild expresses a limited amount, if
any, of p38 N, which lacks the NH2-terminal 13 amino
acid residues. Likewise, in Western blots, wild-type N
and its mutants having an intact NH2-terminal region
gave single protein bands corresponding to proteins
translated from the first methionine of N (Figs. 2A and
3A), in contrast to a doublet of p40 N and p38 N reactive
to anti-N antibody found in BDV-infected cells. These
findings are consistent with the view of Pyper and Gart-
ner (1997) that the p38 N was translated from a short
mRNA which lacked the first AUG codon of the p40
N mRNA.
The physiological roles of the p40 N and p38 N are
unknown. p40 N is targeted to the nucleus where BDV
replicates and may play a central role in this process.
Hsu et al. (1994) found a heterodimer of p40 N and p24,
but not p38 N and p24, in BDV-infected rat brain homo-
genates by immunoprecipitation assay. Likely, the p24-
binding site on p40 N is located in the NH2-terminal 13
amino acid residues which are absent in p38 N. If this is
correct, the p24-binding site will overlap with, or is iden-
tical to, the nuclear localization signal in p40 N. In pre-
liminary experiments, we had cotransfected pcDL-
del.N92 and pcDL-sub.BAS1 into COS-7 cells with a
p24-expressing plasmid. We found that p38 N encoded
by pcDL-del.N92 and the BAS1-substituted mutant of p40
N encoded by pcDL-sub.BAS1 were localized to the
cytoplasm and not in the nucleus (Shoya et al., unpub-
lished results). Thus, not only is p38 N retained in the
cytoplasm, it also does not dimerize with p24. However,
the functional role of p38 N in the cytoplasm of BDV-
infected cells remains to be elucidated.
MATERIALS AND METHODS
BDV and cells
Madin–Darby canine kidney cells persistently infected
with BDV (MDCK/BDV, Herzog and Rott, 1980) were
kindly provided by Dr. R. Rott, Justus-Liebig-Universita¨t
Giessen, Giessen, Germany. The MDCK/BDV cells, non-
infected MDCK cells, and COS-7 cells (Gluzman, 1981)
were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 100 unit/ml
penicillin G, 100 mg/ml streptomycin, and 4 mM glu-
tamine.
Plasmid construction
Plasmids constructed here are schematically shown in
Figs. 1A and 1B, and primers and an adaptor used are
shown in Fig. 1C. A prokaryotic expression plasmid for
BDV N was constructed as follows. Total RNA extracted
from MDCK/BDV cells was reversely transcribed as de-
scribed previously (Shoya et al., 1997). Using the result-
ant cDNA as a template, a DNA fragment containing an
entire BDV N coding sequence was amplified by poly-
merase chain reaction (PCR) with the sense primer 1 and
the antisense primer 2. The amplified DNA fragment was
inserted into the XhoI–KpnI sites of the pTrc-His B plas-
mid (Invitrogen) to give the pTrc-N.Wild. Likewise, the
BDV N cDNA fragment was cloned into the pGEX-5X-3
plasmid (Pharmacia) to give the pGEX-N.Wild, which ex-
presses a glutathione S–transferase (GST)-BDV N fusion
protein in Escherichia coli.
To give a eukaryotic expression plasmid coding for
BDV N, first the pcDL-SRa296 eukaryotic expression
plasmid (Takebe et al., 1988) was modified by replacing
its PstI–KpnI fragment by an adaptor containing a PstI
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site, a Kozak sequence (Kozak, 1991), the DNA fragment
coding for the influenza hemagglutinin (HA) 12CA5
epitope (Wilson et al., 1984), an EcoRI site, a NotI site,
and a KpnI site. The resultant HA-tagged plasmid was
named pcDL-HA. Next, the NotI–KpnI DNA fragment con-
taining an entire BDV N cDNA from pTrc-N.Wild was
cloned into the NotI–KpnI sites immediately downstream
of, and in-frame with, HA in pcDL-HA. The resultant
plasmid was named pcDL-N.Wild, which encodes HA-
fused BDV N.
Eukaryotic expression plasmids encoding a series of
deletion mutants of BDV N (Fig. 1B) were constructed
from the pcDL-N.Wild plasmid by use of the conventional
recombinant DNA techniques, restriction enzymes, and
PCR-mediated mutagenesis. Briefly, an EcoRI–MluI,
EcoRV–KpnI, NarI–KpnI, HindIII–KpnI, or MluI–SnaBI
DNA fragment was removed from pcDL-N.Wild to give
pcDL-del.N369, pcDL-del.C1085, pcDL-del.C940, pcDL-
del.C738, or pcDL-del.M375, respectively. To give pcDL-
del.N92, which encodes an N mutant lacking the 13
NH2-terminal amino acid residues, a DNA fragment
spanning nucleotides (nt) 93–1166 of the BDV N cDNA
fragment in the pcDL-N.Wild vector was amplified by PCR
with sense primer 3 containing a NotI site and primer 2
and then cloned into the NotI–KpnI sites immediately
downstream of, and in-frame with, HA in pcDL-HA. To
construct pcDL-del.N147, which encodes an N mutant
lacking the 32 NH2-terminal amino acid residues, a DNA
fragment spanning nt 148–1166 of the BDV N cDNA was
amplified by PCR with sense primer 4 containing a EcoRI
site and primer 2 and inserted into the pcDL-HA plasmid.
To delete the nucleotide sequence coding for the ba-
sic amino acid stretch 163KKRFK167 (BAS2) of BDV N in
the pcDL-N.Wild, the first round of PCR was performed by
use of primer 1, the antisense primer 5, and pcDL-N.Wild
as a template. This amplified fragment (nt 54 to 572) was
used as a sense primer in the second round of PCR with
primer 2 and the template pcDL-N.Wild. The resultant
DNA fragment with deletion of nt 540–554 for BAS2 was
cloned into the NotI–KpnI sites immediately downstream
of, and in-frame with, HA in pcDL-HA to give pcDL-
del.BAS2 (Fig. 1B). An essentially similar strategy was
employed for construction of pcDL-del.BAS3, which en-
codes an N mutant lacking the 338RYRRREISR346 (BAS3).
In this case, sense primer 6 with deletion of nt 1065–1091
and primer 2 were used in the first round of PCR. The
resultant PCR product was used as an antisense primer
in the second round of PCR with primer 1.
Eukaryotic expression plasmids coding for N mutants
with amino acid substitutions in either BAS2 or BAS3
were constructed by a similar strategy. For example, to
construct the BAS2-substituted plasmid pcDL-sub.BAS2,
which encodes an N mutant with the substitution of
163KKR165 by 163NTS165, sense primer 7 containing the
substitution and primer 2 were used in the first round of
PCR. Likewise, sense primer 8 and primer 2 were used
in the first round of PCR to give pcDL-sub.BAS3, which
encodes the N mutant with the substitution of 340RRR342
by 340TSG342 at BAS3. To construct pcDL-sub.BAS2-3, the
mutant with dual substitutions in BAS2 and BAS3, the
NcoI–NcoI fragment of the pcDL-sub.BAS3 plasmid was
replaced by that of the pcDL-sub.BAS2 construct. To give
the BAS1 (4KRR6)-substituted plasmid pcDL-sub.BAS1, a
DNA fragment containing the 4KRR6 to 4NSG6 substitu-
tion was amplified from pcDL-N.Wild by use of sense
primer 9 containing a NotI site and primer 2. This result-
ant PCR product was directly cloned into the NotI–KpnI
sites of pcDL-HA.
The eukaryotic expression plasmid pRSV-N.LacZ, cod-
ing for codons 3 to 11 (3PKRRLVDDA11) of BDV N fused to
b-galactosidase, was constructed as follows. A 45-bp
DNA fragment containing 59 TAC, a KpnI site, a nucleo-
tide sequence coding the codons 3 to 11 of BDV N, a
KpnI site, and 39 GTA was amplified by use of primers 10
and 11 and pcDL-N.Wild DNA as template. After diges-
tion with KpnI, it was cloned into the KpnI site between
the gpt and the TrpS sequences, and in-frame with the
LacZ gene, in pRSV-LacZ (Koda et al., 1994). This new
construct was named pRSV-N.LacZ. The pRSV-HA plas-
mid was constructed by replacing the LacZ gene in the
pRSV-LacZ vector with the DNA fragment encoding the
HA 12CA5 epitope.
Nucleotide sequences of all recombinant constructs
were confirmed by DNA sequencing by use of an auto-
matic 373A DNA sequencer (Applied Biosystems, Inc.).
The nucleotide and amino acid sequence numbering
used in this report follow those previously reported for a
horse-derived BDV, strain V (the EMBL Databank, Acces-
sion No. U046080).
Antibodies
An anti-BDV N polyclonal serum was prepared by
immunization of a rabbit with the glutathione column-
purified GST-BDV N fusion protein expressed in E. coli.
Mouse monoclonal antibody to the 12CA5 epitope of HA
was purchased from Boehringer Mannheim. A mouse
anti-b-galactosidase monoclonal antibody was from Life
Technologies. A horseradish peroxidase-conjugated
sheep anti-mouse IgG antibody was from Amersham and
a dichlorotriazinylaminofluorescein (DTAF)-conjugated
goat anti-mouse IgG antibody was from Immunotech. A
horseradish peroxidase-conjugated donkey anti-rabbit
IgG antibody was from Amersham, and a DTAF-conju-
gated goat anti-rabbit IgG antibody was from Immuno-
tech.
Expression and detection of proteins in transfected
COS-7 cells
For eukaryotic expression of BDV N, COS-7 cells were
seeded at 2.5 3 105 cells per 35-mm-diameter glass-
bottomed culture dish, and on the next day the cells were
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transfected with 2 mg of DNA plasmids by use of Lipo-
fectamine (Life Technologies). After incubation for 48 h,
the transfected cells were harvested for Western blot
analysis with anti-BDV N serum (1:300 dilution) as first
antibody and a horseradish peroxidase-conjugated don-
key anti-rabbit IgG antiserum (1:1000 dilution) as second-
ary antibody to detect BDV N expression. To detect the
substitution mutants of N and the b-galactosidase pro-
teins, the ECL Western blotting kit (Amersham) was
used. The transfected cells were also subjected to indi-
rect immunofluorescence analysis (IFA) with anti-BDV N
serum (1:500 dilution) or a monoclonal antibody (1:50
dilution) to HA was used as the first antibody. A DTAF-
conjugated goat anti-rabbit IgG antiserum (1:50 dilution)
was used to visualize the subcellular localization of BDV
N. Similarly, a mouse anti-b-galactosidase monoclonal
antibody (1:100 dilution) was used to detect the b-galac-
tosidase proteins. For IFA, the cells were fixed with 4%
paraformaldehyde prior to treatment with 0.4% Triton
X-100 (Ye et al., 1995). After reaction of the antisera, the
stained cells were analyzed on a confocal laser scan-
ning microscope (Meridian Instruments, Inc.). MDCK/
BDV cells were used for the positive control and nonin-
fected MDCK cells or nontransfected COS-7 cells served
as negative controls.
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